Angiodynamics Inc: Form 10-Q for the period ended Nov 30, 2016
Filed with the SEC on Jan 6, 2017 and accepted by EDGAR at Jan 6, 2017, 15:06 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2016-11-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 6 months2016-06-01 to 2016-11-30 | $177.1m | us-gaap:SalesRevenueNet |
| Cost of revenue | 3 months2016-09-01 to 2016-11-30 | $44.0m | us-gaap:CostOfGoodsSold |
| Cost of revenue | 6 months2016-06-01 to 2016-11-30 | $87.1m | us-gaap:CostOfGoodsSold |
| Gross profit | 3 months2016-09-01 to 2016-11-30 | $45.0m | us-gaap:GrossProfit |
| Gross profit | 6 months2016-06-01 to 2016-11-30 | $90.0m | us-gaap:GrossProfit |
| Research and development | 3 months2016-09-01 to 2016-11-30 | $5.9m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2016-06-01 to 2016-11-30 | $12.6m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2016-09-01 to 2016-11-30 | $15.6m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2016-06-01 to 2016-11-30 | $19.2m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2016-09-01 to 2016-11-30 | $813.0k | us-gaap:InterestExpense |
| Interest expense | 6 months2016-06-01 to 2016-11-30 | $1.5m | us-gaap:InterestExpense |
| Income tax | 3 months2016-09-01 to 2016-11-30 | $681.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2016-06-01 to 2016-11-30 | $2.3m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2016-09-01 to 2016-11-30 | $13.7m | us-gaap:NetIncomeLoss |
| Net income | 6 months2016-06-01 to 2016-11-30 | $15.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2016-09-01 to 2016-11-30 | $0.37 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2016-06-01 to 2016-11-30 | $0.41 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2016-09-01 to 2016-11-30 | $0.37 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2016-06-01 to 2016-11-30 | $0.41 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2016-09-01 to 2016-11-30 | 37,146,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2016-06-01 to 2016-11-30 | 37,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2016-06-01 to 2016-11-30 | $22.4m | us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations |
| Capital expenditure | 6 months2016-06-01 to 2016-11-30 | $1.8m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 6 months2016-06-01 to 2016-11-30 | $7.8m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2016-11-30 | $35.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2016-11-30 | $147.8m | us-gaap:AssetsCurrent |
| Total assets | At period end2016-11-30 | $712.2m | us-gaap:Assets |
| Current liabilities | At period end2016-11-30 | $50.8m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2016-11-30 | $188.8m | us-gaap:Liabilities |
| Long-term debt | At period end2016-11-30 | $110.2m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2016-11-30 | $5.0m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2016-11-30 | $523.3m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001275187-17-000005. Last ingested by Listed: Nov 4, 2026, 20:24 ET. Listed shows no prices and gives no investment advice.